Pivotal bioVenture Partners Investment Advisor’s Zenas BioPharma ZBIO Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.6M	Hold	591,991	–	–	4.14%	8
2025 Q4	$21.5M	Sell	591,991 -187,054	-24%	-$6.15M	8.31%	5
2025 Q3	$17.3M	Hold	779,045	–	–	10%	4
2025 Q2	$7.55M	Buy	779,045 +42,400	+6%	+$413K	4.68%	5
2025 Q1	$5.82M	Hold	736,645	–	–	4.71%	4
2024 Q4	$6.03M	Buy	736,645 +85,950	+13%	+$1.34M	4.07%	5
2024 Q3	$11M	Buy	+650,695	New	+$11.7M	6.54%	5

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's ZBIO Position: Q1 2026 in Review

Pivotal bioVenture Partners Investment Advisor held its Zenas BioPharma (ZBIO) position steady in Q1 2026 at 591,991 shares worth $11.6M. The position accounts for 4.14% of the portfolio, ranked #8.

Pivotal bioVenture Partners Investment Advisor first reported a position in ZBIO in Q3 2024 and has held it in 7 quarters since. The position peaked at $21.5M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

Pivotal bioVenture Partners Investment Advisor held 591,991 shares of Zenas BioPharma worth $11.6M as of Q1 2026.
Pivotal bioVenture Partners Investment Advisor left its Zenas BioPharma share count unchanged in Q1 2026.
Zenas BioPharma made up 4.14% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q1 2026, its #8 holding.
Pivotal bioVenture Partners Investment Advisor first reported a position in Zenas BioPharma in Q3 2024 and has held it in 7 quarters since.
Pivotal bioVenture Partners Investment Advisor's Zenas BioPharma position peaked at $21.5M in Q4 2025.
139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.